

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.		
10/005,684 11/08/2001		Aristo Vojdani	IMSCI2.005A 9590		
20995 7	7590 03/28/2005		EXAMINER		
KNOBBE M.	ARTENS OLSON &	YANG, NELSON C			
2040 MAIN S	TREET				
FOURTEENTH FLOOR			ART UNIT	PAPER NUMBER	
IRVINE, CA	92614		1641		

DATE MAILED: 03/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	Applicant(s)		
10/005,684	VOJDANI, ARISTO			
Examiner	Art Unit			
Nelson Yang	1641			

Before the riling of an Appeal Brief	Examiner	Art Unit						
	Nelson Yang	1641						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
THE REPLY FILED 15 March 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.								
1. The reply was filed after a final rejection, but prior to filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL								
2. The reply was filed after the date of filing a Notice of Appeal, but prior to the date of filing an appeal brief. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS								
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);								
(c) ☐ They are not deemed to place the application in be appeal; and/or	 (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or 							
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116 and 41.33(a)).								
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s):								
Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).								
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proof the status of the claim(s) is (or will be) as follows:		vill be entered and an	explanation of					
Claim(s) allowed: Claim(s) objected to:								
Claim(s) rejected: <u>1-12</u> . Claim(s) withdrawn from consideration:								
 AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar 								
and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing	•		·					
entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under apperry and was not earlier presented.	eal and/or appellant fa See 37 CFR 41.33(d)	ails to provide a (1).					
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after	entry is below or atta	thed.					
 11. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: for the reasons discussed in the prior office action. 12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s) 13. ☐ Other: 								
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper	No(s).						
LONG V. LE $\infty/\epsilon_1/\epsilon_2$								
	S	LUNG V. LI UPERVISORY PATEN	E EXAMINER					

TECHNOLOGY CENTER 1600

Continuation of 3. NOTE: the amended claims contain new limitations such as antibodies selected from myosin antibodies, oxidized LDL, heat shock protein-60 and B-2 glycoprotein-1 that would require further consideration and search in order to determine their patentability over the prior art.